TB 301
Alternative Names: TB-301; TNKE-201Latest Information Update: 13 Jan 2023
At a glance
- Originator Therabest Korea
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 21 Dec 2022 Early research in Solid tumours in South Korea (Parenteral) (Therabest Korea pipeline, December 2022)